Fibrosis

Efruxifermin with a glucagon-like peptide-1 receptor agonist was well-tolerated and reduced hepatic fat fraction and noninvasive markers of fibrosis among patients with metabolic dysfunction-associated steatohepatitis and type 2 diabetes.

The organization of cells in scar tissue around pancreatic tumors may help predict survival, according to researchers at Stanford Medicine.

Resmetirom 80 mg and 100 mg outperformed placebo in disease resolution and improvement in liver fibrosis among patients with metabolic dysfunction-associated steatohepatitis, according to 52-week results from the MAESTRO-NASH trial.

Topline findings from a phase 2 trial showed that survodutide achieved “statistically significant improvement” for metabolic dysfunction-associated steatohepatitis and liver fibrosis in 83% of patients, Boehringer Ingelheim announced.

Chronic hepatitis B virus infection was positively linked with severe hepatic necroinflammation in children with metabolic dysfunction-associated steatotic liver disease but did not appear to affect hepatic fibrosis, according to data.

An experimental drug that inhibits aldosterone production reduced albuminuria in patients with chronic kidney disease, according to phase 2 study results published in The Lancet.

Topline data from the phase 2b FASCINATE-2 trial showed “statistically significant improvement” for denifanstat in biopsy-confirmed nonalcoholic steatohepatitis with stage 2 or stage 3 fibrosis at 52 weeks, Sagimet Biosciences announced.

Screening for liver fibrosis was associated with improved self-reported alcohol consumption, diet, exercise and weight after 6 months among patients at risk for liver disease, with lifestyle changes persisting through 2 years.

BOSTON — Healio spoke with James L. Boyer, MD, FACEP, about interim results from the phase 2a INTEGRIS-PSC trial presented at The Liver Meeting, which showed bexotegrast reduced biomarkers of liver fibrosis vs. placebo.

BOSTON — Although primary care physicians play a vital role in managing metabolic dysfunction-associated steatotic liver disease, many are not following guidance on screening, risk stratification or referrals, according to research.